Information from future studies showing differences in the risk of recurrent malignancy associated with haplotype mismatching for specific MHC regions could facilitate development of an immunogenetic approach toward decreasing the risk of acute GVHD while preserving graft-versus-leukemia effects. The gene discussed is HLA-C; the disease is leukemia.